Clinical Trials Logo

Psoriatic Arthritis clinical trials

View clinical trials related to Psoriatic Arthritis.

Filter by:

NCT ID: NCT03320876 Terminated - Psoriatic Arthritis Clinical Trials

An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.

Start date: July 26, 2017
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, open-label, single arm, Long Term Extension (LTE) safety, tolerability and efficacy study of filgotinib in subjects with moderately to severely active PsA. It is estimated that approximately 105 subjects will be rolled-over after they have completed the 16 weeks of double-blind treatment in core study GLPG0634-CL-224. Subjects will be administered filgotinib in this study until filgotinib is registered for PsA or until Week 304, whichever occurs first. The LTE study is concluded with a follow-up visit approximately 4 weeks after the last intake of study treatment.

NCT ID: NCT02841176 Terminated - Psoriatic Arthritis Clinical Trials

Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis

Go-Thermal
Start date: July 2016
Phase: N/A
Study type: Interventional

This study will be an open label pilot study to explore the utility of thermography in assessing response to Golimumab treatment in Psoriatic Arthritis (PsA). Ten patients fulfilling the Classification criteria for Psoriatic Arthritis (CASPAR) for Psoriatic Arthritis with active disease and eligible for anti-TNF therapy will be invited to participate in this study. They will be assessed at 4 time points during the study: prior to their first anti-TNF medication (screening and basal visits), and subsequently within 5 days after their 2nd and 4th doses of monthly Golimumab.

NCT ID: NCT02429895 Terminated - Psoriatic Arthritis Clinical Trials

A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197

Start date: October 2015
Phase: Phase 2
Study type: Interventional

A Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT).

NCT ID: NCT02029495 Terminated - Psoriatic Arthritis Clinical Trials

Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis

AMVISION-1
Start date: March 2014
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16 and week 24. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.

NCT ID: NCT01694264 Terminated - Clinical trials for Rheumatoid Arthritis

Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα

Start date: September 1, 2012
Phase: Phase 3
Study type: Interventional

Analysis of effect of anti-TNFα treatment on HBV reactivation among patients with systemic rheumatic disease, especially rheumatoid arthritis

NCT ID: NCT01516957 Terminated - Psoriatic Arthritis Clinical Trials

AMG 827 in Subjects With Psoriatic Arthritis

Start date: October 2011
Phase: Phase 2
Study type: Interventional

The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis

NCT ID: NCT00534313 Terminated - Psoriatic Arthritis Clinical Trials

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying antirheumatic drugs, including methotrexate and tumor necrosis factor alpha-blockade compounds.